Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Health
STAT+
Biotech
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Pharmalot
STAT+

Did someone say pledge? AbbVie may reverse its promise on price hikes

  • Ed Silverman

By Ed Silverman Sept. 25, 2017

Reprints
AbbVie California
Kristoffer Tripplaar/Sipa/AP

What a difference a few months make.

Just eight months after joining a small but growing list of drug makers that vowed to limit price hikes, AbbVie (ABBV) appears to be backing away from its pledge.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Ed Silverman

Ed Silverman

Pharmalot Columnist, Senior Writer

Ed Silverman covers the pharmaceutical industry.

Tags

Accountable care organizations don’t cut costs. It’s time to…
Accountable care organizations don’t cut costs. It’s time to stop the managed care experiment
6 surprising facts about sugar-laden, virus-fighting breast milk
6 surprising facts about sugar-laden, virus-fighting breast milk
Hospitals are not crumbling, Medicare experts tell Congress
Hospitals are not crumbling, Medicare experts tell Congress
‘That scares me’: New childhood obesity guidelines still face…
‘That scares me’: New childhood obesity guidelines still face a long road to consensus
Takeda autoimmune therapy shows effectiveness in key trial
Takeda autoimmune therapy shows effectiveness in key trial
Moderna CEO made $398 million in 2022, but still…
Moderna CEO made $398 million in 2022, but still pledges to give most to charity

Recommended Stories